| Literature DB >> 29430560 |
Wail Ali1, Beth A Bubolz2, Linh Nguyen3, Danny Castro3, Jorge Coss-Bu3, Michael M Quach4, Curtis E Kennedy3, Anne E Anderson4, Yi-Chen Lai3.
Abstract
OBJECTIVE: Convulsive status epilepticus can exert profound cardiovascular effects in adults including ventricular depolarization-repolarization abnormalities. Whether status epilepticus adversely affects ventricular electrical properties in children is less understood. Therefore, we sought to characterize ventricular alterations and the associated clinical factors in children following convulsive status epilepticus.Entities:
Keywords: ECG; cardiac; children; epilepsy; status epilepticus
Year: 2017 PMID: 29430560 PMCID: PMC5800777 DOI: 10.1002/epi4.12074
Source DB: PubMed Journal: Epilepsia Open ISSN: 2470-9239
Figure 1Case identification and group assignment. There were 4,681 Pediatric Intensive Care Unit (PICU) admissions during the study period, of which 422 children were admitted with a primary diagnosis of status epilepticus. Three hundred seventeen children were eligible, and 59 of these children met inclusion criteria. Twenty‐eight children presented with status epilepticus for the first time and constituted the nonepileptic group, whereas 31 children had a history of epilepsy. ECG, electrocardiogram.
Patient demographics
| Control, n = 31 | Nonepileptic, n = 28 | Epilepsy, n = 31 | p | |
|---|---|---|---|---|
| Age, mo | 79 ± 12 | 49 ± 9 | 71 ± 11 | NS |
| Gender, M/F | 20/11 | 21/7 | 18/13 | NS |
| PICU LOS, days | 3 [0.4–28] | 2 [0.5–18] | 1 [0.5–24] | NS |
| Seizure duration, min | NA | 30 ± 9 | 31 ± 11 | NS |
| Generalized tonic–clonic seizures | 14 (50%) | 18 (58%) | NS | |
| Febrile status epilepticus | NA | 5 (18%) | 0 (0%) | <0.05 |
| Number of acute AEDs | NA | 2 [1–3] | 2 [0–3] | NS |
| Fosphenytoin use | NA | 17 (61%) | 16 (52%) | NS |
| Interval between seizure cessation and ECG, h | NA | 5 [1.5–15] | 3 [1–4.8] | NS |
| ECG indication | ||||
| Seizure etiology evaluation | 0 | 11 (39%) | 5 (16%) | NS |
| Tachycardia | 6 (19%) | 1 (4%) | 2 (7%) | |
| Bradycardia | 2 (6%) | 1 (4%) | 1 (3%) | |
| Atrial tachycardia | 2 (6%) | 0 | 0 | |
| Arrhythmia | 4 (13%) | 4 (14%) | 6 (19%) | |
| Evaluate ST segment | 0 | 6 (21%) | 8 (26%) | |
| Evaluate QT interval | 1 (3%) | 2 (7%) | 4 (13%) | |
| Evaluate heart disease | 9 (29%) | 0 | 0 | |
| Chest pain | 3 (10%) | 0 | 0 | |
| Other | 4 (13%) | 3 (11%) | 5 (16%) |
Values are expressed as mean ± standard error of the mean, median [min–max], or n (%).
AED, antiepileptic drug; ECG, electrocardiogram; F, female; LOS, length of stay; M, male; NS, not significant; PICU, Pediatric Intensive Care Unit.
n = 22.
n = 25.
Other indications include syncope, murmur, hypertension, and hyperkalemia.
Primary outcomes by group assignment
| Control, n = 31 | Nonepileptic, n = 28 | OR [95% CI] | Epilepsy, n = 31 | OR [95% CI] | |
|---|---|---|---|---|---|
| Abnormal ECG | 8 (26%) | 12 (43%) | 3.8 [1.3–11.5] | 22 (71%) | 7.0 [2.3–21.5] |
| ST segment changes | 4 (13%) | 9 (32%) | 3.2 [0.9–11.9] | 18 (58%) | 9.3 [2.6–33.3] |
| Abnormal T wave morphology | 3 (10%) | 11 (39%) | 6.0 [1.5–24.8] | 10 (32%) | 4.4 [1.1–18.2] |
| Abnormal QRS axis | 1 (3%) | 5 (18%) | 6.5 [0.7–44.6] | 8 (26%) | 10.3 [1.2–89.5] |
| Prolonged QTc interval | 0 | 1 (4%) | 3.4 [0.13–87.9] | 4 (13%) | 10.3 [0.5–200.3] |
Values are expressed as relative risk [95% CI].
CI, confidence interval; ECG, electrocardiogram; OR, odds ratio; QTc, corrected QT.
p < 0.05, p < 0.001 versus control group.
All counts adjusted by 0.5 to allow estimation of RR.
Figure 2Status epilepticus–associated ventricular abnormalities and instability. (A) Sample lead II electrocardiogram tracings. Arrows indicate ST segment changes, abnormal T wave morphology, and QRS axis deviation. Lines indicate prolonged corrected QT (QTc). (B) Scatter diagrams of QT and the corresponding RR intervals from the control, nonepileptic, and epileptic groups. Linear regression (solid line) and the 95% confidence interval (dashed lines) demonstrate the best goodness‐of‐fit in the control group (r2 = 0.87). The nonepileptic group has decreased goodness‐of‐fit (r2 = 0.75), and the epileptic group has the least goodness‐of‐fit (r2 = 0.6). The epileptic group also exhibits a flatten slope as compared with the control group. (C) Poincaré plots of the QTc intervals from the control, nonepileptic, and epileptic groups. The control group had QTc values that center on the line of identity. The QTc values scatter around the line of identity in the nonepileptic and epileptic groups, with the most prominent dispersion in the epileptic group. Short‐term variability (STV) representing the mean orthogonal distance to the line of identity shows higher values in the nonepileptic and epileptic groups as compared with the control group. STV is presented as mean ± standard error of the mean. *p < 0.05, ***p < 0.001 versus control group.
Secondary outcomes and laboratory data by group assignment
| Control, n = 31 | Nonepileptic, n = 28 | Epilepsy, n = 31 | p | |
|---|---|---|---|---|
| HR, bpm | 132 ± 7 | 130 ± 5 | 124 ± 6 | NS |
| PR, ms | 115 ± 5 | 119 ± 4 | 123 ± 4 | NS |
| QRS, ms | 71 ± 4 | 79 ± 6 | 80 ± 10 | NS |
| QTc, ms | 414 ± 3 | 416 ± 3 | 412 ± 5 | NS |
| SaO2 | 97 ± 0.4 | 99 ± 0.5 | 98 ± 0.4 | NS |
| pH | 7.30 ± 0.02 | 7.30 ± 0.02 | 7.21 ± 0.04 | NS |
| pCO2, mmHg | 46 ± 4 | 49 ± 3 | 53 ± 4 | NS |
| HCO3, mEq/L | 22 ± 1 | 23 ± 1 | 21 ± 1 | NS |
| BE | −4.0 ± 1.1 | −3.3 ± 1.0 | −5.7 ± 1.2 | NS |
| Glucose, mg/dL | 143 ± 78 | 116 ± 47 | 131 ± 70 | NS |
| Na+, mmol/L | 138 ± 4.5 | 137 ± 3.0 | 139 ± 4.6 | NS |
| K+, mmol/L | 4.0 ± 0.7 | 4.0 ± 0.5 | 4.2 ± 0.7 | NS |
| Ca2+, mg/dL | 8.6 ± 0.3 | 9.2 ± 0.1 | 9.3 ± 0.1 | 0.03 |
| Mg+, mg/dL | 2.1 ± 0.3 | 2.0 ± 0.3 | 2.4 ± 1.6 | NS |
Values are expressed as mean ± standard error of the mean.
BE, base excess; HR, heart rate; NS, not significant; QTc, corrected QT; SaO2, oxygen saturation.
n = 25, n = 24, n = 20, n = 27, n = 24, n = 30, n = 28, n = 24, n = 29.
*p < 0.05 versus control, post hoc Tukey.
Clinical factors of seizure patients by ECG findings
| Normal ECG, n = 25 | Abnormal ECG, n = 34 | p | |
|---|---|---|---|
| Gender, M/F | 16/9 | 23/11 | NS |
| Age, mo | 71 ± 58 | 52 ± 53 | NS |
| PICU LOS, days | 2 [0.8–9] | 2 [0.5–24] | NS |
| HR, bpm | 127 ± 30 | 126 ± 30 | NS |
| PR interval, ms | 121 ± 20 | 122 ± 20 | NS |
| QRS interval, ms | 80 ± 46 | 80 ± 46 | NS |
| QTc interval, ms | 414 ± 23 | 414 ± 23 | NS |
| pH | 7.29 ± 0.03 | 7.25 ± 0.03 | NS |
| pCO2, mmHg | 49 ± 3 | 53 ± 4 | NS |
| HCO3, mEq/L | 22 ± 1 | 23 ± 1 | NS |
| BE | −4.1 ± 0.9 | −4.7 ± 1.2 | NS |
| Electrolyte abnormality | 4 (16%) | 11 (32%) | NS |
| Serum Ca2+, mg/dL | 9.2 ± 0.2 | 9.2 ± 0.1 | NS |
| Seizure duration, min | 29 ± 6 | 38 ± 8 | NS |
| Number of acute AEDs | 2 [0–3] | 2 [0–3] | NS |
| Fosphenytoin | 16 (64%) | 19 (56%) | NS |
| Benzodiazepines | 22 (88%) | 24 (71%) | NS |
| Levetiracetam | 3 (12%) | 10 (29%) | NS |
| Phenobarbital | 3 (12%) | 1 (3%) | NS |
| History of epilepsy | 9 (36%) | 22 (65%) | 0.04 |
| Duration of epilepsy, mo | 16 [7.3–88.5] | 16 [6.5–61] | NS |
| Generalized tonic–clonic seizures | 6/9 (67%) | 15/22 (68%) | NS |
| Number of chronic AEDs | 1 [0–3] | 1 [0–5] | NS |
Values are expressed as mean ± standard error of the mean, median [min–max], or n (%).
AED, antiepileptic drug; BE, base excess; ECG, electrocardiogram; F, female; HR, heart rate; LOS, length of stay; M, male; NS, not significant; PICU, Pediatric Intensive Care Unit; QTc, corrected QT.
n = 21, n = 29, n = 18, n = 31, n = 10, n = 21.